glp-1 gip The Effects of Dual GLP-1/GIP Receptor Agonism on Glucagon Secretion—A Review The dual glucose-dependent insulinotropic polypeptide

Weight loss remains a central therapeutic driver: A reduction in body weight of at least 7 to 10 percent resolves NASH in approximately 65 to 90 percent of patients

Less visceral fat means lower inflammatory cytokines, better glucose control, improved lipid profiles, and reduced cardiometabolic risk

Health Qual Life Outcomes

I am hoping to continue in my fitness and weight-loss journey." Dawn I have [lost] 53 pounds since October so far on the [GLP-1] injection

In addition to promoting hypoglycemic effects, they can increase the number of cells in the pancreas, block cell death, and boost insulin production [90], [91]

So this makes a whole lot of sense